- Home
- IVDA vs GRI Comparison
IVDA vs GRI Comparison
Compare IVDA & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVDA
- GRI
- Stock Information
- Founded
- IVDA 2003
- GRI 2018
- Country
- IVDA United States
- GRI United States
- Employees
- IVDA N/A
- GRI N/A
- Industry
- IVDA Computer Software: Prepackaged Software
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- IVDA Technology
- GRI Health Care
- Exchange
- IVDA Nasdaq
- GRI Nasdaq
- Market Cap
- IVDA 4.3M
- GRI 4.3M
- IPO Year
- IVDA N/A
- GRI N/A
- Fundamental
- Price
- IVDA $0.81
- GRI $1.69
- Analyst Decision
- IVDA
- GRI Strong Buy
- Analyst Count
- IVDA 0
- GRI 2
- Target Price
- IVDA N/A
- GRI $22.50
- AVG Volume (30 Days)
- IVDA 252.9K
- GRI 157.7K
- Earning Date
- IVDA 11-14-2025
- GRI 11-14-2025
- Dividend Yield
- IVDA N/A
- GRI N/A
- EPS Growth
- IVDA N/A
- GRI N/A
- EPS
- IVDA N/A
- GRI N/A
- Revenue
- IVDA $6,395,925.00
- GRI N/A
- Revenue This Year
- IVDA $340.48
- GRI N/A
- Revenue Next Year
- IVDA N/A
- GRI N/A
- P/E Ratio
- IVDA N/A
- GRI N/A
- Revenue Growth
- IVDA 20.56
- GRI N/A
- 52 Week Low
- IVDA $0.71
- GRI $1.10
- 52 Week High
- IVDA $8.05
- GRI $16.95
- Technical
- Relative Strength Index (RSI)
- IVDA 28.67
- GRI 44.78
- Support Level
- IVDA $0.71
- GRI $1.56
- Resistance Level
- IVDA $0.90
- GRI $1.89
- Average True Range (ATR)
- IVDA 0.10
- GRI 0.15
- MACD
- IVDA -0.03
- GRI -0.01
- Stochastic Oscillator
- IVDA 14.45
- GRI 29.17
About IVDA Iveda Solutions Inc.
Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.